THR. Oxurion NV

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:

Oxurion received a transparency notification on July 17, 2024, from Atlas Special Opportunities, LLC indicating that as of July 17, 2024, it held 941,611,204 shares of the then outstanding 12,275,690,851 shares, and therefore crossed below the threshold (10%) by virtue of the sale of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at .

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV

Pascal Ghoson

Chief Executive Officer

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

Attachment



EN
18/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oxurion NV

 PRESS RELEASE

Oxurion Share Consolidation

Oxurion Share Consolidation Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, authorized by the General Meeting of July 24, 2024, will proceed with a consolidation of all existing shares. This consolidation will be carried out at a ratio of one (1) new share for ten thousand (10,000) existing shares. This share consolidation is a strategic step to increase the nominal value of the shares, simplify the capital structure, and improve th...

 PRESS RELEASE

Oxurion Announces Results on the Extraordinary General Meeting (EGM) o...

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting. All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion’s website . About Oxurion Oxur...

 PRESS RELEASE

Information on the Total Number of Voting Rights (Denominator) followi...

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, ...

 PRESS RELEASE

Oxurion Receives Transparency Notification from Atlas Special Opportun...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 17, 2024, from Atlas Special Opportunities, LLC indicating that as of July 17, 2024, it held 941,611,204 shares of the then o...

 PRESS RELEASE

Oxurion provides clarification on the agenda of the extraordinary gene...

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, announced today it has provided clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 (the EGM) as set out in the convening notice published on 5 July 2024 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch